Abbott Reveals Q4 and Full-Year 2025 Results; Shares 2026 Financial Outlook
Abbott Laboratories has released its financial results for the fourth quarter and full year ending December 31, 2025. The company reported strong growth, demonstrating its resilience and strategic planning in an evolving healthcare landscape.
Key Financial Highlights from Q4 and FY 2025
In the fourth quarter, Abbott achieved a total revenue of $11.459 billion, representing a 4.4% increase compared to the same period in 2024. Adjusted diluted earnings per share (EPS) reached $1.50, marking a 12% growth. The company’s GAAP diluted EPS stood at $1.01.
For the full year 2025, Abbott reported total sales of $44.328 billion, a 5.7% increase from 2024. The adjusted diluted EPS for the year was $5.15, reflecting a 10% growth.
2026 Financial Outlook
Looking ahead, Abbott projects an organic sales growth between 6.5% and 7.5% for the full year 2026. The adjusted diluted EPS for 2026 is expected to range from $5.55 to $5.80, also indicating a substantial growth trajectory.
Fourth Quarter Breakdown: Business Segments
- Nutrition: Sales decreased by 8.9% on a reported basis.
- Diagnostics: Sales reported at $2.457 billion, down 2.5% compared to Q4 2024.
- Established Pharmaceuticals: Achieved a sales increase of 9.0% internationally.
- Medical Devices: Total sales increased by 12.3%, with notable growth in Electrophysiology and Diabetes Care.
Strategic Initiatives
Abbott is poised for growth in the cancer diagnostics market with its planned acquisition of Exact Sciences, anticipated to close in Q2 2026. Additionally, Abbott received significant FDA approvals for its Volt
PFA System and CE Mark for its TactiFlex Duo Ablation Catheter, enhancing its expertise in Electrophysiology.
Dividends and Shareholder Returns
On December 12, 2025, Abbott declared its quarterly dividend of $0.63 per share. This marks the 408th consecutive quarterly dividend, showcasing Abbott’s commitment to returning value to its shareholders.
Conclusion
Abbott Laboratories has demonstrated solid performance in 2025, and projections for 2026 highlight the company’s ongoing commitment to growth and innovation. With strategic acquisitions and new product launches in the pipeline, Abbott is well-positioned to tackle future challenges and capitalize on emerging opportunities in the healthcare sector.
